EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clarithromycin Use in the First Trimester Is Not Associated With Fetal Abnormalities

Tomo Suzuki iD, Mikako Goto iD, Tatsuhiko Anzai, Ritsuko Yamane, Omi Watanabe, Kunihiko Takahashi, Atsuko Murashima

Congenital Anomalies · 2026-01 · 66 (1)

DOI: 10.1002/cga.70041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Congenital Anomalies, online erschienen am 16.02.2026. Verfasst von Tomo Suzuki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Japan Drug Information Institute in Pregnancy, Integrated Center for Women's Health, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Clarithromycin, Anti-Bacterial Agents, Abnormalities, Drug-Induced. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clarithromycin is a macrolide antibiotic that is widely used, including during pregnancy. However, few studies have examined the safety of clarithromycin alone in early pregnancy. In this two‐center retrospective cohort study, we evaluated pregnancy outcomes following first‐trimester clarithromycin exposure. Information on medication use and obstetric history was obtained retrospectively. Pregnancy outcomes were collected using patient‐completed postal questionnaires. We investigated pregnancy outcomes and the incidence of major anomalies in women who took clarithromycin during the first trimester, and compared them with those in women who took β‐lactams or control drugs known to be safe during pregnancy. The primary outcome was the incidence of major anomalies, and the secondary outcome was overall pregnancy outcomes. The numbers of major anomalies in the clarithromycin group ( n = 347), β‐lactam group ( n = 1367), and control group ( n = 1313) were 8 (2.31%), 26 (1.90%), and 18 (1.37%), respectively. When restricted to patients with live births only, the numbers of major anomalies in these groups ( n = 333, n = 1323, and n = 1261, respectively) were 8 (2.40%), 25 (1.89%), and 18 (1.43%), respectively, with no significant differences between groups. The odds ratio for major anomalies in the clarithromycin group relative to the control group was 1.70 (95% confidence interval [CI], 0.73–3.94), while that relative to the β‐lactam group was 1.28 (95% CI, 0.57–2.86). Inverse probability weighting to compensate for small sample sizes also yielded no significant differences. Overall, clarithromycin use during the first trimester was not associated with an increased risk of major anomalies relative to β‐lactams or control drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClarithromycinAnti-Bacterial AgentsAbnormalities, Drug-InducedHumansFemalePregnancyPregnancy Trimester, FirstRetrospective StudiesPregnancy OutcomeAdult

Stichwörter der Autor:innen

antibioticclarithromycinfetal abnormalitiespregnancyβ‐Lactams

Substanzen

ClarithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Japan Drug Information Institute in Pregnancy, Integrated Center for Women's Health, National Center for Child Health and Development, Tokyo, Japan.
  • Division of Obstetrics, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Biostatistics, M&D Data Science Center, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Pharmacy, Toranomon Hospital, Tokyo, Japan.
  • Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama, Japan.

ORCID-Profile: Tomo Suzuki, Mikako Goto

Förderung

  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Suzuki, T., Goto, M., Anzai, T., Yamane, R., Watanabe, O., Takahashi, K., & Murashima, A. (2026). Clarithromycin Use in the First Trimester Is Not Associated With Fetal Abnormalities. Congenital Anomalies, 66(1). https://doi.org/10.1002/cga.70041

Vancouver

Suzuki T, Goto M, Anzai T, Yamane R, Watanabe O, Takahashi K, et al. Clarithromycin Use in the First Trimester Is Not Associated With Fetal Abnormalities. Congenital Anomalies. 2026;66(1). doi:10.1002/cga.70041

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Tomo and Goto, Mikako and Anzai, Tatsuhiko and Yamane, Ritsuko and Watanabe, Omi and Takahashi, Kunihiko and Murashima, Atsuko},
  title = {Clarithromycin Use in the First Trimester Is Not Associated With Fetal Abnormalities},
  journal = {Congenital Anomalies},
  year = {2026},
  volume = {66},
  number = {1},
  doi = {10.1002/cga.70041}
}
Kostenlos starten →